[1]杨金伟,马楠楠,屈重阳,等.曲妥珠单抗对人表皮生长因子受体-2阳性乳腺癌患者的心血管毒性研究进展[J].新乡医学院学报,2022,39(4):396-400.[doi:10.7683/xxyxyxb.2022.04.020]
　YANG Jinwei,MA Nannan,QU Chongyang,et al.Research progress on cardiovascular toxicity of trastuzumab in patients with human epidermal growth factor receptor-2 positive breast cancer[J].Journal of Xinxiang Medical University,2022,39(4):396-400.[doi:10.7683/xxyxyxb.2022.04.020]
点击复制

曲妥珠单抗对人表皮生长因子受体-2阳性乳腺癌患者的心血管毒性研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年4
页码:
396-400
栏目:
综述
出版日期:
2022-04-05

文章信息/Info

Title:
Research progress on cardiovascular toxicity of trastuzumab in patients with human epidermal growth factor receptor-2 positive breast cancer
作者:
杨金伟1; 2; 马楠楠1; 2; 屈重阳1; 2; 杜梦楠1; 2; 张　莹1; ２
（1.天津中医药大学第一附属医院，天津　300381；2.国家中医针灸临床医学研究中心，天津　300381）
Author(s):
YANG Jinwei1; 2; MA Nannan1; 2; QU Chongyang1; 2; DU Mengnan1; 2; ZHANG Ying1; 2
（1.The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine，Tianjin 300381,China;2.National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion，Tianjin 300381,China）
关键词:
曲妥珠单抗; 乳腺癌; 心血管毒性; 人表皮生长因子受体-2
Keywords:
trastuzumab; breast cancer; cardiovascular toxicity; human epidermal growth factor receptor-2
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2022.04.020
文献标志码:
A
摘要:
曲妥珠单抗作为人表皮生长因子受体-2（HER-2）的特异性拮抗剂，可延长HER-2阳性乳腺癌患者的生存期，目前已成为HER-2阳性乳腺癌患者治疗的基础选择药物。曲妥珠单抗总体安全性较好，但临床中引起的心血管毒性事件也不容忽视。本文综述了曲妥珠单抗在HER-2阳性乳腺癌患者治疗中所致心血管毒性的临床表现、发生率、发生机制、高危因素、监测及防治，以期为临床安全用药提供参考。
Abstract:
Trastuzumab,as a specific antagonist of human epidermal growth factor receptor-2 (HER-2),can prolong the survival of patients with HER-2 positive breast cancer.Trastuzumab has now become the basic drug of choice for the treatment of patients with HER-2 positive breast cancer.The overall safety of trastuzumab is good,but the clinical cardiovascular toxicity events cannot be ignored.This article reviews the clinical manifestations,incidence,mechanism,high-risk factors,monitoring and prevention of trastuzumab-induced cardiovascular toxicity in patients with HER-2 positive breast cancer,in order to provide a reference for clinical safe drug use.

参考文献/References:

［1］　郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2019,41(1):19-28.
ZHENG R S,SUN K X,ZHANG S W,et al.Report of cancer epidemiology in China,2015［J］.Chin J Oncol,2019,41(1):19-28.
［2］　MILLER K,CORTES J,HURVITZ S A,et al.HERMIONE:a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician′s choice plus trastuzumab in patients with previously treated,anthracycline-nave,HER2-positive,locally advanced/metastatic breast cancer［J］.BMC Cancer,2016,16:352.
［3］　AN J,SHEIKH M S.Toxicology of trastuzumab:an insight into mechanisms of cardiotoxicity［J］.Curr Cancer Drug Targets,2019,19(5):400-407.
［4］　GRADISHAR W J,ANDERSON B O,ABRAHAM J,et al.Breast cancer,version 3.2020,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2020,18(4):452-478.
［5］　许凤锐,江泽飞.人表皮生长因子受体2阳性乳腺癌诊疗新进展及解析［J］.中华医学杂志,2020,100(30):2324-2327.
XU F R,JIANG Z F.Key points of diagnosis and treatment for HER2 positive breast cancer［J］.Natl Med J China,2020,100(30):2324-2327.
［6］　LI J,WANG S,WANG Y,et al.Disparities of trastuzumab use in resource-limited or resource-abundant regions and its survival benefit on HER2 positive breast cancer:a real-world study from China［J］.Oncologist,2017,22(11):1333-1338.
［7］　ZAMORANO J L,LANCELLOTTI P,RODRIGUEZ MUNOZ D,et al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines:the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)［J］.Eur Heart J,2016,37(36):2768-2801.
［8］　胡志强,余文韬,姚文秀,等.抗肿瘤药物致心脏毒性及其防治措施的研究进展［J］.中国药房,2020,31(2):250-256.
HU Z Q,YU W T,YAO W X,et al.Research progress on cardiotoxicity induced by antitumor drugs and its preventive measures［J］.China Pharm,2020,31(2):250-256.
［9］　ADVANI P P,BALLMAN K V,DOCKTER T J,et al.Long-term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial［J］.J Clin Oncol,2016,34(6):581-587.
［10］　VALICSEK E,KOSZO R,DOBI A,et al.Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer［J］.Anticancer Res,2015,35(9):4967-4973.
［11］　GRAZZIOTIN L R,PICON P D.Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer［J］.J Oncol Pharm Pract,2017,23(4):264-272.
［12］　DENEGRI A,MOCCETTI T,MOCCETTI M,et al.Cardiac toxicity of trastuzumab in elderly patients with breast cancer［J］.J Geriatr Cardiol,2016,13(4):355-363.
［13］　曾化桂.HER-2阳性乳腺癌抗HER-2药物治疗的心脏毒性研究进展［J］.临床肿瘤学杂志,2017,22(4):362-368.
ZENG H G.Progression of cardiotoxicity due to anti-HER-2 medication on patients with HER-2 positive breast cancer［J］.Chin Clin Oncol,2017,22(4):362-368.
［14］　何丹,丁瑞麟.分子靶向药物心脏毒性线粒体机制的研究进展［J］.四川生理科学杂志,2019,41(4):309-312.
HE D,DING R L.Advances on the mitochondrial mechanism of cardiotoxicity of targeted drugs［J］.Sichuan J Physiol Scien,2019,41(4):309-312.
［15］　VARGA Z V,FERDINANDY P,LIAUDET L,et al.Drug-induced mitochondrial dysfunction and cardiotoxicity［J］.Am J Physiol Heart Circ Physiol,2015,309(9):H1453- H1467.
［16］　石远凯,巴一,冯继锋,等.中国蒽环类药物特性专家共识［J］.中国肿瘤临床,2018,45(3):109-112.
SHI Y K,BA Y,FENG J F,et al.Expert consensus on characteristics of anthracyclines in China［J］.Chin J Clin Oncol,2018,45(3):109-112.
［17］　NEMETH B T,VARGA Z V,WU W J,et al.Trastuzumab cardiotoxicity:from clinical trials to experimental studies［J］.Br J Pharmacol,2017,174(21):3727-3748.
［18］　李小敏,姜馨.乳腺癌相关心血管疾病的研究进展［J］.中国分子心脏病学杂志,2020,20(4):3501-3504.
LI X M,JIANG X.Research progress of cardiovascular damage related to breast cancer［J］.Mol Cardiol China,2020,20(4):3501-3504.
［19］　徐虹,冀学宁.曲妥珠单抗在Her-2阳性乳腺癌治疗中的心脏毒性［J］.中国实用医药,2019,14(13):183-186.
XU H,JI X N.Cardiotoxicity of trastuzumab in Her-2 positive breast cancer［J］.China Pract Med,2019,14(13):183-186.
［20］　陈浩然,孔令泉,吴凯南.乳腺癌靶向治疗相关心脏毒性防治的研究进展［J］.中国临床新医学,2019,12(4):361-365.
CHEN H R,KONG L Q,WU K N.Advances in the prophylaxis and treatment of cardiotoxicity associated with targeted therapy of breast cancer［J］.Chin J New Clin Med,2019,12(4):361-365.
［21］　董超,杨润祥.乳腺癌药物治疗所致的心脏毒性与对策［J］.中国临床医生杂志,2017,45(4):1-3.
DONG C,YANG R X.Cardiotoxicity and countermeasures caused by drug therapy of breast cancer［J］.Chin J Clin,2017,45(4):1-3.
［22］　DEMPSEY N,ROSENTHAL A,DABAS N,et al.Trastuzumab-induced cardiotoxicity:a review of clinical risk factors,pharmacologic prevention,and cardiotoxicity of other HER2-directed therapies［J］.Breast Cancer Res Treat,2021,188(1):21-36.
［23］　CAMERON D,PICCART-GEBHART M J,GELBER R D,et al.11 years′ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer:final analysis of the HERceptin Adjuvant (HERA) trial［J］.Lancet,2017,389(10075):1195-1205.
［24］　田方圆,张莹,陈昭燕,等.降低曲妥珠单抗使用时间对HER-2阳性乳腺癌患者影响的系统评价［J］.药物流行病学杂志,2019,28(1):10-14.
TIAN F Y，ZHANG Y，CHEN Z Y，et al.Effectiveness of reducing trastuzumab use time on HER-2 positive breast cancer patients:a systematic review［J］.Chin J Pharmacoepidemiol,2019,28(1):10-14.
［25］　FLORIDO R,SMITH K L,CUOMO K K,et al.Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies［J］.J Am Heart Assoc,2017,6(9):e006915.
［26］　SLAMON D,EIERMANN W,ROBERT N,et al.Adjuvant trastuzumab in HER2-positive breast cancer［J］.N Engl J Med,2011,365(14):1273-1283.
［27］　ANASTASIOU M,OIKONOMOU E,VOGIATZI G,et al.Differential effect of anthracycline and trastuzumab cancer therapeutic related vascular toxicity in patients with breast cancer［J/OL］.Eur Heart J,2020,41(S2):ehaa946.3287［2020.11.25］.https://doi.org/10.1093/ehjci/ehaa946.3287.
［28］　DALL P,LENZEN G,GOHLER T,et al.Trastuzumab in the treatment of elderly patients with early breast cancer:results from an observational study in Germany［J］.J Geriatr Oncol,2015,6(6):462-469.
［29］　LYON A R,DENTS,STANWAY S,et al.Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies:a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the european society of cardiology in collaboration with the international cardio-oncology society［J］.Eur J Heart Fail,2020,22(11):1945-1960.
［30］　KOSALKA P,JOHNSON C,TUREK M,et al.Effect of obesity,dyslipidemia,and diabetes on trastuzumab-related cardiotoxicity in breast cancer［J］.Curr Oncol,2019,26(3):e314-e321.
［31］　曾慧,唐雪苗.曲妥珠单抗在乳腺癌患者治疗中的心脏毒性［J］.实用医学杂志,2017,33(12):2056-2058.
ZENG H,TANG X M.Cardiotoxicity of trastuzumab in breast cancer patients［J］.J Pract Med,2017,33(12):2056-2058.
［32］　高晓丽.抗肿瘤药的心脏毒性［J］.西南医科大学学报,2019,42(5):483-488.
GAO X L.Cardiotoxicity of antitumor drugs［J］.J Southwest Med Univ,2019,42(5):483-488.
［33］　蒋瑶,牟霜,谭开彬.二维斑点追踪成像评价乳腺癌曲妥珠单抗化疗亚临床心脏毒性的价值［J］.临床超声医学杂志,2020,22(1):33-37.
JIANG Y，MOU S，TAN K B.Evaluation of subclinical cardiotoxicity associated with trastuzumab chemotherapy in patients with breast cancer by two-dimensional speckle tracking imaging［J］.J Clin Ultrasound in Med,2020,22(1):33-37.
［34］　LOFFLER A I,SALERNO M.Cardiac MRI for the evaluation of oncologic cardiotoxicity［J］.J Nucl Cardiol,2018,25(6):2148-2158.
［35］　黄平,高柳村,邵喜英,等.曲妥珠单抗相关心脏毒性监测研究进展［J］.转化医学电子杂志,2017,4(4):74-77.DOI:10.3969/j.issn.2095-6894.2017.04.09.
HUANG P,GAO L C,SHAO X Y,et al.Research progress on monitoring trastuzumab related cardiotoxicity［J］.E-J Transl Med,2017,4(4):74-77.DOI:10.3969/j.issn.2095-6894.2017.04.09.
［36］　中华医学会肿瘤学分会乳腺肿瘤学组,中国乳腺癌靶向治疗药物安全性管理共识专家组.中国乳腺癌靶向治疗药物安全性管理专家共识［J］.中国癌症杂志,2019,29(12):993-1006.
BREAST ONCOLOGY GROUP OF ONCOLOGY BRANCH OF CHINESE MEDICAL ASSOCIATION,EXPERT GROUP OF CONSENSUS EXPERT GROUP ON DRUG SAFETY MANAGEMENT OF TARGETED THERAPY FOR BREAST CANCER IN CHINA.Expert consensus on the safety management of targeted therapy for breast cancer in China［J］.China Oncol,2019,29(12):993-1006.
［37］　俸艳英.乳腺癌治疗相关心脏毒性及防治研究进展［J］.中国癌症防治杂志,2019,11(6):540-544.
FENG Y Y.Research progress of breast cancer treatment-related cardiotoxicity and its prevention and treatment［J］.Chin J Oncol Prev Treat,2019,11(6):540-544.
［38］　张洋,刘晓菲,朱睛,等.加味生脉饮对HER-2阳性乳腺癌赫赛汀所致心脏毒性防治作用研究［J］.现代中西医结合杂志,2020,29(24):2640-2643,2683.
ZHANG Y,LIU X F,ZHU Q,et al.Study on the prevention and treatment effect of Jiawei Shengmaiyin on the cardiotoxicity caused by Herceptin in HER-2 positive breast cancer［J］.Mod J Integr Tradit Chin West Med,2020,29(24):2640-2643,2683.
［39］　姚铁柱,徐志宏,马景涛,等.心脉隆注射液对曲妥珠单抗和蒽环类药物序贯化疗乳腺癌患者致心脏毒性气虚血瘀证的保护作用［J］.中国实验方剂学杂志,2016,22(6):154-158.
YAO T Z,XU Z H,MA J T,et al.Protection effect of Xinmailong Injection in treating breast cancer patients with myocardial damage caused by sequential chemotherapy of trastuzumab and anthracyclines［J］.Chin J Exp Tradit Med Formulae,2016,22(6):154-158.
［40］　张至惠,胡述博,王志峰,等.补肾活血汤联合曲妥珠单抗治疗Her-2阳性晚期乳腺癌临床疗效及对患者免疫功能的影响［J］.世界中医药,2019,14(4):993-996.
ZHANG Z H,HU S B,WANG Z F,et al.Clinical effects of Bushen Huoxue Decoction combined with trastuzumab in treating HER-2 positive advanced breast cancer and its effects on patient′s immune function［J］.World Chin Med,2019,14(4):993-996.

相似文献/References:

[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 ． 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王　乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]王妍妍,赵永新,王建强,等.乳腺肿块患者血清和肿块组织中B细胞淋巴瘤因子3蛋白的表达及临床意义[J].新乡医学院学报,2021,38(7):649.[doi:10.7683/xxyxyxb.2021.07.010]
　WANG Yanyan,ZHAO Yongxin,WANG Jianqiang,et al.Clinical significance and expression of B-cell lymphoma factor 3 protein in serum and mass tissue of breast mass patients[J].Journal of Xinxiang Medical University,2021,38(4):649.[doi:10.7683/xxyxyxb.2021.07.010]
[11]张　婷,刘起鹏,郭婉莹,等.曲妥珠单抗联合术前新辅助化学治疗对乳腺癌患者肿瘤标志物、血管内皮因子和凋亡因子的影响及疗效观察[J].新乡医学院学报,2020,37(11):1075.[doi:10.7683/xxyxyxb.2020.11.016]
　ZHANG Ting,LIU Qipeng,GUO Wanying,et al.Effect of trastuzumab combined with neoadjuvant chemotherapy on tumor markers,vascular endothelial growth factor and apoptotic factors in patients with breast cancer and therapeutic effect analysis[J].Journal of Xinxiang Medical University,2020,37(4):1075.[doi:10.7683/xxyxyxb.2020.11.016]
[12]李小峰,孙新宇,张　慧.曲妥珠单抗联合紫杉醇和卡铂治疗人表皮生长因子受体-2阳性乳腺癌的疗效及其对心功能的影响[J].新乡医学院学报,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]
　LI Xiaofeng,SUN Xinyu,ZHANG Hui.Effect of trastuzumab combined with paclitaxel and carboplatin in the treatment of patients with human epidermal growth factor receptor-2-positive breast cancer and its effect on cardiac function[J].Journal of Xinxiang Medical University,2022,39(4):376.[doi:10.7683/xxyxyxb.2022.04.016]

更新日期/Last Update: 2022-04-05